Opus Genetics, Inc. (IRD)
3.83
-0.01
(-0.26%)
USD |
NASDAQ |
Oct 19, 15:49
Opus Genetics Enterprise Value : 264.76M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 264.76M |
| October 15, 2026 | 282.12M |
| October 14, 2026 | 286.25M |
| October 13, 2026 | 297.82M |
| October 12, 2026 | 330.88M |
| October 09, 2026 | 331.70M |
| October 08, 2026 | 316.00M |
| October 07, 2026 | 311.87M |
| October 06, 2026 | 309.39M |
| October 05, 2026 | 309.39M |
| October 02, 2026 | 325.92M |
| October 01, 2026 | 320.13M |
| September 30, 2026 | 347.41M |
| September 29, 2026 | 356.91M |
| September 28, 2026 | 364.76M |
| September 25, 2026 | 340.80M |
| September 24, 2026 | 349.89M |
| September 23, 2026 | 346.58M |
| September 22, 2026 | 373.86M |
| September 21, 2026 | 378.81M |
| September 18, 2026 | 375.51M |
| September 17, 2026 | 383.77M |
| September 16, 2026 | 394.52M |
| September 15, 2026 | 428.40M |
| September 14, 2026 | 440.80M |
| Date | Value |
|---|---|
| September 11, 2026 | 446.59M |
| September 10, 2026 | 449.06M |
| September 09, 2026 | 420.96M |
| September 08, 2026 | 306.08M |
| September 04, 2026 | 333.36M |
| September 03, 2026 | 327.57M |
| September 02, 2026 | 315.18M |
| September 01, 2026 | 263.93M |
| August 31, 2026 | 246.58M |
| August 28, 2026 | 252.36M |
| August 27, 2026 | 265.59M |
| August 26, 2026 | 261.45M |
| August 25, 2026 | 287.07M |
| August 24, 2026 | 280.46M |
| August 21, 2026 | 282.12M |
| August 20, 2026 | 287.90M |
| August 19, 2026 | 283.77M |
| August 18, 2026 | 252.36M |
| August 17, 2026 | 249.06M |
| August 14, 2026 | 245.75M |
| August 13, 2026 | 254.84M |
| August 12, 2026 | 258.15M |
| August 11, 2026 | 268.07M |
| August 10, 2026 | 249.88M |
| August 07, 2026 | 249.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Rezolute, Inc. | 238.27M |
| Faeth Therapeutics, Inc. | 306.58M |
| Nuvectis Pharma, Inc. | 474.36M |
| ACADIA Pharmaceuticals, Inc. | 2.409B |
| Alnylam Pharmaceuticals, Inc. | 30.68B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.098M |
| Revenue (Quarterly) | 0.755M |
| Total Expenses (Quarterly) | 8.853M |
| EPS Diluted (Quarterly) | -0.139 |
| Gross Profit Margin (Quarterly) | 98.15% |
| Profit Margin (Quarterly) | -1.07K% |
| Earnings Yield | -35.95% |
| Normalized Earnings Yield | -22.36 |